Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.

@article{Nutt2008EffectsOA,
  title={Effects of a NR2B selective NMDA glutamate antagonist, CP-101,606, on dyskinesia and Parkinsonism.},
  author={John G. Nutt and Steven A. Gunzler and Trish Kirchhoff and Penelope Hogarth and Jerry L Weaver and Michael Krams and Brenda D Jamerson and Frank S. Menniti and Jaren W. Landen},
  journal={Movement disorders : official journal of the Movement Disorder Society},
  year={2008},
  volume={23 13},
  pages={1860-6}
}
Glutamate antagonists decrease dyskinesia and augment the antiparkinsonian effects of levodopa in animal models of Parkinson's disease (PD). In a randomized, double-blind, placebo-controlled clinical trial, we investigated the acute effects of placebo and two doses of a NR2B subunit selective NMDA glutamate antagonist, CP-101,606, on the response to 2-hour… CONTINUE READING